F an ovulation triggering agent, human chorionic gonadotropin (hCG), versus a
F an ovulation triggering agent, human chorionic gonadotropin (hCG), versus a gonadotropin-releasing hormone agonist (GnRHa) on early embryo development in vitro using a time-lapse system. Methods: Retrospective analysis of a prospectively collected database. A total of 739 embryos from 152 infertile couples Varlitinib site undergoing intracytoplasmic sperm injection cycles. Interventions : Embryo culture in a time-lapse incubator (EmbryoScope, Vitrolife, G eborg, Sweden). Main Outcome Measures: Embryo morphokinetic parameters. Results: In the 152 women, 252 embryos were derived from GnRHa-triggered cycles compared with 487 embryos derived from hCG-triggered cycles. Time-lapse analysis revealed that embryos from cycles triggered by a GnRHa cleaved faster than embryos derived from hCG-triggered cycles. Conclusion: Triggering with a GnRHa in in vitro fertilization cycles affects embryo kinetics. Keywords: Agonist trigger, Oocyte, Embryo quality, Time lapse, MorphokineticBackground Embryo quality is one of the most important factors affecting the success of in vitro fertilization (IVF). Currently, embryo quality is determined using morphological evaluation methods, and in most circumstances the embryologist’s decision is the last step in choosing the embryo that is transferred to the patient. Although morphological evaluation has been the gold standard for many years, it is a subjective process with inter- and intra-observer variability [1]. It is also a static evaluation method, and some abnormalities cannot be detected PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25112874 over the time interval involved in embryo evaluation. Time-lapse monitoring is a new technology that enables dynamic, more objective evaluation of embryos [2, 3]. The treatment protocol and duration and the type and dosage of drugs are clinician-dependent factors that might affect oocyte and embryo quality. Initially, IVF* Correspondence: [email protected] 1 Novafertil IVF Centre, Yeni Meram yolu No:75, Meram, Konya, Turkey Full list of author information is available at the end of the articletreatment was performed in a natural cycle; however, over the last 20 years many different treatment protocols have been used [4]. Gonadotropin-releasing hormone agonists (GnRHa) have long been used to inhibit premature luteinizing hormone (LH) release. In the last decade, however, a GnRH antagonist protocol has become preferred for pituitary desensitization worldwide, because it is a more patient friendly approach that also reduces the risk of ovarian hyperstimulation syndrome (OHSS) [5]. Another advantage of antagonist cycles is they enable the use of a GnRHa for triggering final oocyte maturation. There are some physiological differences between human chorionic gonadotropin (hCG) and GnRHa triggers. Unlike hCG triggering of final oocyte maturation, GnRHa triggering is a more physiological approach, eliciting a surge of gonadotropins similar to that of the natural mid-cycle surge [6]. The serum LH and follicle-stimulating hormone (FSH) levels rise after 4 and 12 h, respectively, and are elevated for 24?6 h. The amplitudes of the surge are similar to?2016 Gurbuz et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26100631 (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indic.
